Back
PER
Percheron Therapeutics Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-17.14%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
4
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
📈 Performance
Price History
-92.00%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PER
4
📊 Total Capital Earnings
$3K
🔃 Average investment frequency
16 weeks
💵 Average investment amount
$1,390
⏰ Last time a customer invested in PER
120 days
PER investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50%
50k - 100k
Less than 50k
50%
👶 Age of investors
18 - 25
26 - 34
25%
35 - 90
75%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in PER also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
7.95%
📊 Share price
$105.69 AUD
🧱 MATERIALS
🇦🇺 AUSTRALIA
💸 FINANCIALS
⛳️ DIVERSIFIED
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
20.30%
📊 Share price
$49.75 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
🇺🇸 UNITED STATES
Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The firm's principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. The firm's other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users.
🙌 Performance (5Yr p.a)
-8.76%
📊 Share price
$0.09 AUD
🩺 HEALTH CARE
Accent Group Ltd. operates as an investment holding company, which engages in the retail of performance and lifestyle footwear. The company is headquartered in Richmond, Victoria. The company went IPO on 2004-07-07. The firm operates approximately 903 stores across 18 different retail banners, and distribution rights for 12 international brands across Australia and New Zealand. The firm operates through two segments: Retail and Wholesale. The Retail segment is engaged in selling of footwear and apparel directly to consumers. The Wholesale segment is engaged in selling of footwear and apparel in bulk internally and to other businesses. The Company’s banners and brands include Platypus Shoes, The Athlete’s Foot (TAF), Hype DC, Skechers, Merrell, Vans, Dr. Martens, Saucony, Timberland, HOKA, Superga, Subtype, Stylerunner, Glue Store, Nude Lucy and UGG.
🙌 Performance (5Yr p.a)
0.30%
📊 Share price
$1.34 AUD
💰 HIGH DIVIDEND
🛍️ CONSUMER
Want more shares? Try these...
